Moleculin Biotech Highlights Annamycin's Safety Profile in CEO Corner
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 07 2026
0mins
Should l Buy MBRX?
Source: Newsfilter
- Safety Advantage: CEO Walter Klemp emphasizes Annamycin's non-cardiotoxic profile, specifically designed to avoid cardiac damage associated with traditional anthracyclines like doxorubicin, thereby expanding treatment options for patients with relapsed or refractory acute myeloid leukemia (AML).
- Clinical Trial Progress: The company is advancing its MIRACLE study, evaluating Annamycin in combination with cytarabine for AML patients, which is expected to significantly improve patient outcomes and reshape treatment paradigms in oncology.
- Regulatory and Commercial Outlook: Annamycin's unique safety profile may provide physicians with more flexible treatment strategies, while also yielding favorable regulatory and commercial implications, enhancing the company's competitive position in the oncology market.
- Pipeline Expansion: In addition to Annamycin, Moleculin is developing candidates like WP1066 and WP1122 targeting brain tumors, pancreatic cancer, and pathogenic viruses, further enriching its therapeutic pipeline and strengthening its market position in oncology and antiviral treatments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MBRX
Wall Street analysts forecast MBRX stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.440
Low
20.00
Averages
24.33
High
31.00
Current: 2.440
Low
20.00
Averages
24.33
High
31.00
About MBRX
Moleculin Biotech, Inc. is a Phase III clinical-stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing tumors and viruses. The Company is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Moleculin Biotech Reports FY EPS of -$28.42
- Financial Performance: Moleculin Biotech reported a fiscal year EPS of -$28.42, indicating significant challenges in profitability that could impact investor confidence and lead to stock price volatility.
- Cash Position: As of December 31, 2025, the company had cash and cash equivalents of $8.9 million and prepaid expenses and other current assets of $0.8 million, suggesting a degree of liquidity but highlighting the need for overall financial improvement.
- Funding Activities: Moleculin Biotech secured $8.3 million from warrant exercises, providing essential operational funding to support its R&D and operational activities, although the efficiency of subsequent fund utilization remains a concern.
- Market Sentiment: Seeking Alpha's Quant Rating on Moleculin Biotech reflects a cautious market outlook regarding its future performance, prompting investors to closely monitor the company's subsequent financial results and strategic adjustments.
See More
U.S. Stocks Close Lower, Dow Jones Falls Over 300 Points
- Market Performance: U.S. stocks closed lower on Thursday, with the Dow Jones index dropping over 300 points, a decline of 0.64% to 49,346.38, indicating investor concerns about the economic outlook.
- Walmart Earnings: Walmart reported upbeat fourth-quarter results with adjusted earnings per share of 74 cents, exceeding the expected 73 cents, but its fiscal 2027 outlook fell short, projecting earnings between $2.75 and $2.85, below the consensus estimate of $2.96.
- Sales Growth: Walmart's sales reached $190.70 billion, a 5.6% year-over-year increase, surpassing the analyst consensus of $190.43 billion, demonstrating the company's strong performance in the retail market.
- Energy Stocks Rise: Despite the overall market decline, energy stocks gained 1.1%, reflecting investor confidence in the sector, likely driven by oil prices rising 2.1% to $66.53.
See More
U.S. Stocks Open Lower with Dow Down Over 250 Points
- Market Performance: U.S. stocks opened lower this morning, with the Dow Jones index dropping over 250 points, a decline of 0.54% to 49,394.62, indicating weakened market sentiment that could impact investor confidence.
- Jobless Claims Data: Initial jobless claims in the U.S. fell by 23,000 to 206,000, below market expectations of 225,000, suggesting a resilient labor market that may positively influence economic recovery.
- Energy Stocks Rise: Energy shares gained 1.5% on Thursday, reflecting optimistic expectations for energy demand, which could present profit growth opportunities for related companies.
- Commodity Market Dynamics: Oil prices increased by 2.1% to $66.55, while gold rose 0.1% to $5,012.00, indicating heightened demand for safe-haven assets, which may influence future investment strategies.
See More
Moleculin Biotech Exercises Warrants for $8.3M
- Financing Scale: Moleculin Biotech has entered agreements for the immediate exercise of warrants covering 2.12 million shares at $3.90 each, expected to generate approximately $8.3 million in gross proceeds before advisory fees, thereby enhancing the company's liquidity.
- New Warrants Issuance: The company will issue new unregistered five-year warrants to purchase up to 6.37 million shares, with an exercise price set at the lower of $3.90 or the lowest VWAP during the next five trading days, increasing financing flexibility.
- Use of Proceeds: The transaction is expected to close around February 20, 2026, with net proceeds allocated for working capital and general corporate purposes, indicating the company's proactive planning for future operations.
- Market Reaction: The exercise of warrants and the new issuance plan may boost market confidence in Moleculin Biotech's financial health, potentially leading to a positive impact on its stock price.
See More
Moleculin Launches CEO Corner Platform for Investor Insights
- CEO Corner Launch: Moleculin Biotech announced the launch of its CEO Corner on February 13, 2026, designed to provide deeper insights into corporate developments and clinical progress from CEO Walter Klemp, thereby enhancing trust among investors and stakeholders.
- Clinical Trial Progress: The company is conducting the MIRACLE clinical trial to evaluate Annamycin in combination with cytarabine for treating relapsed acute myeloid leukemia (AML), paving the way for potential drug approval and demonstrating the company's commitment to advancing its pipeline.
- Drug Development Strategy: Annamycin, a next-generation oncology drug, aims to avoid multidrug resistance and reduce cardiotoxicity, expected to provide effective solutions for AML and soft tissue sarcoma, thereby enhancing the company's competitive position in cancer treatment.
- Enhanced Investor Engagement: The CEO Corner platform allows investors to submit questions and topics, facilitating direct communication with the company, reflecting Moleculin's emphasis on transparency and timely communication to enhance long-term shareholder value.
See More
Moleculin Biotech's 2026 MIRACLE Trial Data Unblinding Expected
- Clinical Trial Progress: Moleculin expects to complete the unblinding of data for 45 subjects in the MIRACLE trial in Q1 2026, which is anticipated to provide critical efficacy data for treating acute myeloid leukemia (AML), thereby enhancing Annamycin's market recognition.
- New Indication Expansion: Annamycin is set to initiate a clinical trial for pancreatic cancer in 2026, funded by Atlantic Health, based on preclinical data showing unexpected activity in pancreatic cancer models, further enhancing its market potential.
- Global Trial Network: The MIRACLE trial has expanded to nine countries, including the US and several European nations, with 46 trial sites selected, and is expected to recruit the 90th subject by Q1 2026, demonstrating the company's strong execution capabilities on a global scale.
- Significant Market Opportunity: Annamycin is poised to become the world's first non-cardiotoxic anthracycline, and given that nearly half of cancer patients currently use cardiotoxic drugs, the market demand potential is enormous, likely attracting increased investor interest.
See More
Moleculin Biotech Reports FY EPS of -$28.42
- Financial Performance: Moleculin Biotech reported a fiscal year EPS of -$28.42, indicating significant challenges in profitability that could impact investor confidence and lead to stock price volatility.
- Cash Position: As of December 31, 2025, the company had cash and cash equivalents of $8.9 million and prepaid expenses and other current assets of $0.8 million, suggesting a degree of liquidity but highlighting the need for overall financial improvement.
- Funding Activities: Moleculin Biotech secured $8.3 million from warrant exercises, providing essential operational funding to support its R&D and operational activities, although the efficiency of subsequent fund utilization remains a concern.
- Market Sentiment: Seeking Alpha's Quant Rating on Moleculin Biotech reflects a cautious market outlook regarding its future performance, prompting investors to closely monitor the company's subsequent financial results and strategic adjustments.
See More
U.S. Stocks Close Lower, Dow Jones Falls Over 300 Points
- Market Performance: U.S. stocks closed lower on Thursday, with the Dow Jones index dropping over 300 points, a decline of 0.64% to 49,346.38, indicating investor concerns about the economic outlook.
- Walmart Earnings: Walmart reported upbeat fourth-quarter results with adjusted earnings per share of 74 cents, exceeding the expected 73 cents, but its fiscal 2027 outlook fell short, projecting earnings between $2.75 and $2.85, below the consensus estimate of $2.96.
- Sales Growth: Walmart's sales reached $190.70 billion, a 5.6% year-over-year increase, surpassing the analyst consensus of $190.43 billion, demonstrating the company's strong performance in the retail market.
- Energy Stocks Rise: Despite the overall market decline, energy stocks gained 1.1%, reflecting investor confidence in the sector, likely driven by oil prices rising 2.1% to $66.53.
See More
U.S. Stocks Open Lower with Dow Down Over 250 Points
- Market Performance: U.S. stocks opened lower this morning, with the Dow Jones index dropping over 250 points, a decline of 0.54% to 49,394.62, indicating weakened market sentiment that could impact investor confidence.
- Jobless Claims Data: Initial jobless claims in the U.S. fell by 23,000 to 206,000, below market expectations of 225,000, suggesting a resilient labor market that may positively influence economic recovery.
- Energy Stocks Rise: Energy shares gained 1.5% on Thursday, reflecting optimistic expectations for energy demand, which could present profit growth opportunities for related companies.
- Commodity Market Dynamics: Oil prices increased by 2.1% to $66.55, while gold rose 0.1% to $5,012.00, indicating heightened demand for safe-haven assets, which may influence future investment strategies.
See More
Moleculin Biotech Exercises Warrants for $8.3M
- Financing Scale: Moleculin Biotech has entered agreements for the immediate exercise of warrants covering 2.12 million shares at $3.90 each, expected to generate approximately $8.3 million in gross proceeds before advisory fees, thereby enhancing the company's liquidity.
- New Warrants Issuance: The company will issue new unregistered five-year warrants to purchase up to 6.37 million shares, with an exercise price set at the lower of $3.90 or the lowest VWAP during the next five trading days, increasing financing flexibility.
- Use of Proceeds: The transaction is expected to close around February 20, 2026, with net proceeds allocated for working capital and general corporate purposes, indicating the company's proactive planning for future operations.
- Market Reaction: The exercise of warrants and the new issuance plan may boost market confidence in Moleculin Biotech's financial health, potentially leading to a positive impact on its stock price.
See More
Moleculin Launches CEO Corner Platform for Investor Insights
- CEO Corner Launch: Moleculin Biotech announced the launch of its CEO Corner on February 13, 2026, designed to provide deeper insights into corporate developments and clinical progress from CEO Walter Klemp, thereby enhancing trust among investors and stakeholders.
- Clinical Trial Progress: The company is conducting the MIRACLE clinical trial to evaluate Annamycin in combination with cytarabine for treating relapsed acute myeloid leukemia (AML), paving the way for potential drug approval and demonstrating the company's commitment to advancing its pipeline.
- Drug Development Strategy: Annamycin, a next-generation oncology drug, aims to avoid multidrug resistance and reduce cardiotoxicity, expected to provide effective solutions for AML and soft tissue sarcoma, thereby enhancing the company's competitive position in cancer treatment.
- Enhanced Investor Engagement: The CEO Corner platform allows investors to submit questions and topics, facilitating direct communication with the company, reflecting Moleculin's emphasis on transparency and timely communication to enhance long-term shareholder value.
See More
Moleculin Biotech's 2026 MIRACLE Trial Data Unblinding Expected
- Clinical Trial Progress: Moleculin expects to complete the unblinding of data for 45 subjects in the MIRACLE trial in Q1 2026, which is anticipated to provide critical efficacy data for treating acute myeloid leukemia (AML), thereby enhancing Annamycin's market recognition.
- New Indication Expansion: Annamycin is set to initiate a clinical trial for pancreatic cancer in 2026, funded by Atlantic Health, based on preclinical data showing unexpected activity in pancreatic cancer models, further enhancing its market potential.
- Global Trial Network: The MIRACLE trial has expanded to nine countries, including the US and several European nations, with 46 trial sites selected, and is expected to recruit the 90th subject by Q1 2026, demonstrating the company's strong execution capabilities on a global scale.
- Significant Market Opportunity: Annamycin is poised to become the world's first non-cardiotoxic anthracycline, and given that nearly half of cancer patients currently use cardiotoxic drugs, the market demand potential is enormous, likely attracting increased investor interest.
See More
